Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Relay Therapeutics (RLAY) over the last 5 years, with Q3 2025 value amounting to 0.49%.

  • Relay Therapeutics' Return on Capital Employed fell 200.0% to 0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.46% for FY2024, which is 700.0% down from last year.
  • Per Relay Therapeutics' latest filing, its Return on Capital Employed stood at 0.49% for Q3 2025, which was down 200.0% from 0.47% recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Return on Capital Employed registered a high of 0.09% during Q1 2021, and its lowest value of 0.49% during Q3 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.41% (2022), whereas its average is 0.39%.
  • Over the last 5 years, Relay Therapeutics' Return on Capital Employed had its largest YoY gain of 1700bps in 2022, and its largest YoY loss of -3200bps in 2022.
  • Over the past 5 years, Relay Therapeutics' Return on Capital Employed (Quarter) stood at 0.45% in 2021, then skyrocketed by 37bps to 0.28% in 2022, then plummeted by -58bps to 0.44% in 2023, then increased by 1bps to 0.44% in 2024, then dropped by -12bps to 0.49% in 2025.
  • Its Return on Capital Employed stands at 0.49% for Q3 2025, versus 0.47% for Q2 2025 and 0.46% for Q1 2025.